Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017

Albumin-bilirubin grade predicts prognosis in HCC

06 Jul 2017

Albumin-bilirubin (ALBI) grade may predict prognosis in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE), a new study shows.

The study included 881 HCC patients receiving TACE (median age 68 years; 76 percent male) and showing a median overall survival of 24 months. Hepatitis B (35 percent, n=311) and C (27 percent; n=241), and alcoholism (19 percent; n=162) were the principal causes of HCC.

Of all the tested markers, ALBI grade resulted in the highest homogeneity (43.655) and lowest corrected Akaike information criteria (AICc) value (8,094.296). This was followed by cirrhosis discriminant index (CDS; 35.635 and 8,102.143, respectively) and Child-Turcotte-Pugh score (CTP; 26.861 and 8,111.090, respectively).

Univariate survival analysis showed that alcoholism (hazard ratio [HR], 1.240; 95 percent CI, 1.018 to 1.509; p=0.032), alkaline phosphatase level (HR, 1.678; 1.435 to 1.963; p<0.001), vascular invasion (HR, 2.511; 2.075 to 3.039; p<0.001) and ALBI grades 2 (HR, 1.678; 1.421 to 1.981; p<0.001) and 3 (HR, 1.501; 1.251 to 1.801; p<0.001) were all indicators of poor prognosis.

Multivariate analysis confirmed the significant association of alkaline phosphatase level (HR, 1.362; 1.155 to 1.607; p<0.001), vascular invasion (HR, 1.999; 1.622 to 2.464; p<0.001) and ALBI grade 2 (HR, 1.531; 1.285 to 2.823; p<0.001) to reduced survival.

ALBI grade 3 (HR, 1.525; 0.976 to 2.382l; p=0.064) was only modestly associated with poor survival.

Participants with histologically confirmed HCC were recruited from the Taipei Veterans General Hospitals.

Aside from ALBI, CTP and CDS, the prognostic performances of the following liver reserve markers were also assessed: aspartate transaminase-to-platelet ratio (APRI), fibrosis index based on four factors (FIB-4), Göteborg University Cirrhosis Index (GUCI), model for end-stage liver disease (MELD) and Lok index.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017